What is your preferred first line approach to patients with Stage IV non-squamous NSCLC with good performance status, no driver mutations, PD-L1 low-positive, and CKD IIIB or worse, CrCl < 45 mL/min?  

Assuming the patient had no contraindications to immunotherapy and no other significant comorbidities.

Answer from: Medical Oncologist at Community Practice